 |
03-07-2009, 03:44 AM
|
#1
|
|
Senior Member
Join Date: Mar 2006
Posts: 4,778
|
HERA and FinHER studies results to be updated at next week's St Gallen conference
So says Dr Unch at this week's Miami Breast Cancer Conference...
Perhaps the results of 1 vs 2 years' Herceptin?
Stay tuned...
|
|
|
|
03-07-2009, 09:37 AM
|
#2
|
|
Senior Member
Join Date: Sep 2005
Location: Stockton, NJ
Posts: 4,179
|
Thanks so much for this information. Especially the 1 vs 2 yrs of adjuvant Herceptin. Perfect timing for some of the people on this board that are still in adjuvant treatment!
__________________
Kind regards
Becky
Found lump via BSE
Diagnosed 8/04 at age 45
1.9cm tumor, ER+PR-, Her2 3+(rt side)
2 micromets to sentinel node
Stage 2A
left 3mm DCIS - low grade ER+PR+Her2 neg
lumpectomies 9/7/04
4DD AC followed by 4 DD taxol
Used Leukine instead of Neulasta
35 rads on right side only
4/05 started Tamoxifen
Started Herceptin 4 months after last Taxol due to
trial results and 2005 ASCO meeting & recommendations
Oophorectomy 8/05
Started Arimidex 9/05
Finished Herceptin (16 months) 9/06
Arimidex Only
Prolia every 6 months for osteopenia
NED 18 years!
Said Christopher Robin to Pooh: "You must remember this: You're braver than you believe and stronger than you seem and smarter than you think"
|
|
|
|
|
03-07-2009, 10:38 AM
|
#3
|
|
Senior Member
Join Date: Feb 2008
Location: Georgia
Posts: 1,486
|
Lani,
Was the conference this week or is it next week?
Amelia
|
|
|
|
|
03-07-2009, 12:37 PM
|
#4
|
|
Senior Member
Join Date: Jun 2006
Location: San Antonio, TX
Posts: 2,357
|
Can't wait to hear these results! ma
__________________
MA in TX.
Grateful for each and every day....
Diag. 12/05 at age 60
Stage II, Grade 3, 4.5 cm primary tumor
ER/PR- Her2 +3 strongly positive
Her2 by FISH 7.7 amplified
vascular invasion
Ki67 20% borderline
Jan - March '06 Taxotere/Adriamycin X 3 to try to shrink tumor - it grew
April '06 Rt Modified Radical Mas, 7 of 9 nodes positive
April - Aug. '06 Herceptin/Taxol/Carboplatin X 8 (dose dense)
Sept - Dec. '06 Navelbine/Herceptin x 8 (dose dense)
Radiation & Herceptin Jan. 22 - March 1, 2007
Finished Herceptin Dec. 10 '08! One extra year.
Port removed August, 2012.
8 1/2 years since diagnosis! 5 1/2 Years NED!
|
|
|
|
|
03-07-2009, 11:07 PM
|
#5
|
|
Senior Member
Join Date: Mar 2006
Posts: 4,778
|
the Miami Breast cancer conference ran the 3rd/4th-7th
the St. Gallen conference begins next week
|
|
|
|
|
03-08-2009, 03:29 PM
|
#6
|
|
Senior Member
Join Date: Sep 2005
Posts: 414
|
Thanks again, Lani
It will be interesting to see how these trials have panned out.
|
|
|
|
|
03-10-2009, 01:57 AM
|
#7
|
|
Senior Member
Join Date: Oct 2006
Location: I live in Christmas, MI - located on the shores of Lake Superior.
Posts: 606
|
Thanks as always Lani!
__________________
Barb
10/03 Radical Mastectomy 3 cm tumor - 1/17 Nodes Stage II B, Her 2 +++ ER-/PR- 11/03 4 AC 4 Taxol 12/05 Stage IV - Lung met , Bone mets - Carbo, Taxotere, Herceptin 9/06 - 2 cm brain tumor 10/06 - Tumor removal surgery - Herceptin Halted 12/06 gamma knife tumor base.1/07 Navelbine/Herceptin 4/07 Rads to R femur 5/07 Stereotactic - new 2 cm brain tumor 4/07 Start Xeloda 5/07 Tykerb added 7/07 Brain MRI clean 10/07 .055 cm brain met found. 12/07 Stereotactic -1 cm brain tumor Start Tykerb 11/07 Abraxane/Herceptin 5/08 Cisplatin, Gemcitabine/Herceptin 6/08 Stereotactic to 1cm 9/08 Stereotactic repeat (growth). 11/08 Pet Scan Good but new tiny met on L lung/dead Brain surgery (no cancer cells found/scar tissue) 1/09 Chemo restarted 2/09 Pet Scan Bad - R larger very active/active L active lymph nodes both sides of chest MRI- mets slight increase 2/09 Start Doxil/Tykerb Treatment
|
|
|
|
|
03-10-2009, 04:59 AM
|
#8
|
|
Senior Member
Join Date: Oct 2007
Posts: 1,851
|
Lani,
I've been thinking about the FinHER trail and wondering whether early stage bc patients will be able to have a shorter course of Herceptin that would be just as effective.
If so it would be great news for bc patients, but bad news for Genentech which is now involved in a hostile takeover by Roche.
Joan
__________________
Diagnosed stage 2b in July 2003 (2.3 cm, HER2+, ER-/PR-, 7+ nodes). Treated with mastectomy (with immediate DIEP flap reconstruction), AC + T/Herceptin (off label). Cancer advanced to lung in Jan. 2007 (1 cm nodule). Started Herceptin every 3 weeks. Lung wedge resection April 2007. Cancer recurred in lung April 2008. RFA of lung in August 2008. 2nd annual brain MRI in Oct. 2008 discovered 2.6 cm cystic tumor in left frontal lobe. Craniotomy Oct. 2008 (ER-/PR-/HER2-) followed by targeted radiation (IMRT). Coughing up blood Feb. 2009. Thoractomy July 2009 to cut out fungal ball of common soil fungus (aspergillus) that grew in the RFA cavity (most likely inhaled while gardening). No cancer, only fungus. Removal of tiny melanoma from upper left arm, plus sentinel lymph node biopsy in Feb. 2016. Guardant Health liquid biopsy in Feb. 2016 showed mutations in 4 subtypes of TP53. Repeat of Guardant Health biopsy in Jana. 2021 showed 3 TP53 mutations, BRCA1 mutation and CHEK2 mutation. Invitae genetic testing showed negative for all of these. Living with MBC since 2007. Stopped Herceptin Hylecta (injection) treatment in March 2020. Recent 2021 annual CT of chest, abdomen and pelvis and annual brain MRI showed NED. Praying for NED forever!!
|
|
|
|
|
03-11-2009, 10:55 PM
|
#9
|
|
Senior Member
Join Date: Mar 2006
Posts: 4,778
|
according to the schedule the FinHer and Hera updates are Thursday around 5pm CET
Doesn't look like this meeting has podcasts so I will have to look for press-releases, etc.
|
|
|
|
|
03-14-2009, 02:13 PM
|
#10
|
|
Senior Member
Join Date: Sep 2005
Posts: 414
|
FinHer reports out five year followup
http://www.docguide.com/news/content...2575780065EE72
This is pretty raw stuff, pretty much a straight abstract, but I will see if I can make it a bit simpler. I hope Lani will correct anything that I have gotten wrong.
The interesting findings:
* Taxotere was clearly better than vinorelbine for early BC.
* The reduction in overall mortality in the group that got herceptin and taxotere was 58% in the Finher protocol.
* There seems to have a been a big and significant reduction in distant mets when herceptin was used with taxotere. The abstract is written in such a confusing manner that I struggled with it, but I think the risk of distant mets was reduced by about half. There was a significant improvement in distant disease free survival.
* The herceptin-treated group did not have more heart problems than the control group.
Questions left unanswered:
* There was no confidence interval provided for the hazard reduction in the abstract, so it is impossible to know what the margin of error on the recurrence reduction is to compare it to other trials. This is a particularly important omission given the relatively small size of the trial.
* Why they used distant disease free survival instead of the more usual disease free survival.
* There were no confidence intervals or p values given for the overall improvement in survival, which probably means that this trial has not yet demonstrated that herceptin significantly improves mortality, but updated figures on this are also missing from four year HERA results as well. Maybe it is all those her2-positive women with secondaries living a long time on herceptin complicating things!
I guess we will have to wait until it is published for more answers.
|
|
|
|
|
03-14-2009, 07:01 PM
|
#11
|
|
Senior Member
Join Date: Jul 2006
Posts: 463
|
Christine, thanks for this. I agree, it's jumbled - you did a good job trying to translate. And it's a newsperson's interpretation of the abstract. I wish that the website for this conference had some information.
The information about Herceptin (except at the end, talking about cancer-free survival) did have significance - they gave the p-values and those were okay, right?
We've been spoiled by SABCS and ASCO and their nearly real-time reports, huh?
Debbie Laxague
__________________
3/01 ~ Age 49. Occult primary announced by large (6cm) axillary node, found by my husband.
4/01 ~ Bilateral mastectomies (LMRM, R elective simple) - 1.2cm IDC was found at pathology. 5 of 11 axillary nodes positive, largest = 6cm. Stage IIIA
ERPR 5%/1% (re-done later at Baylor, both negative at zero).
HER2neu positive by IHC and FISH (8.89).
Lymphovascular invasion, grade 3, 8/9 modified SBR.
TX: Control of arm of NSABP's B-31 adjuvant Herceptin trial (no Herceptin, inducing a severe case of Herceptin-envy): A/C x 4 and Taxol x 4 q3weeks, then rads. Raging infection of entire chest after small revision of mastectomy scar after completing tx (significance unknown). Arimidex for two years, stopped after second pathology opinion.
2017: Mild and manageable lymphedema and some cognitive issues.
|
|
|
|
|
03-15-2009, 02:32 PM
|
#12
|
|
Senior Member
Join Date: Sep 2005
Posts: 414
|
P values
The only p-value given was for distant disease free survival, but it would meet a standard 5% cutoff. P equalled .029 for adding herceptin to taxotere, so there was less than a 3% chance that the increase in distant disease free survival was a fluke.
You're right, Debbie, it was probably a journalist's interpretation of the abstract, which explains some of the weirdness of it. If that was the case, the lack of confidence intervals might just be down to a tight deadline. I would hope that a medical professional would pay more attention to confidence intervals. Well, at least someone bothered to write about the results for this trial, so we should be thankful for that.
In my experience, Europe generally just tends to be more secretive about things than America is, which may help to explain why the abstracts are not more freely available. Of course, St Gallen is in Switzerland, which has a reputation for being especially secretive.
|
|
|
|
Posting Rules
|
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts
HTML code is Off
|
|
|
All times are GMT -7. The time now is 07:15 PM.
|
Linear Mode
